may30,2013–GlaxoSmithKline (GSK) and Genmab (GEN) have announced positive results from Phase III study of Arzerra (ofatumumab) in combination with chlorambucil for the treatment of chronic lymphocytic leukaemia (CLL) patients.
![FORTEO (teriparatide [rDNA origin]) Structural Formula Illustration](http://images.rxlist.com/images/rxlist/forteo1.gif)
New Data on FORTEO® (teriparatide [rDNA origin] injection) Show Increased Bone Mineral Density in Men with Glucocorticoid-Induced Osteoporosis
http://www.pharmalive.com/study-lillys-forteo-increases-bone-mineral-density-in-men
 |
|
Example of an Ensemblin™
|
Ensemble Therapeutics today announced that preclinical data showing the advantages of its Ensemblins, novel macrocyclic compounds against challenging drug targets, will be presented at the 245th American Chemical Society (ACS) National Meeting …
Ensemblins™ are a new class of synthetic macrocycles developed by Ensemble using its proprietary chemistry platforms, including DNA-Programmed Chemistry. Macrocyclic rings are found in many natural product-based drugs and bestow favorable pharmaceutical properties and powerful protein surface binding properties upon such drugs. Thus, macrocycles are uniquely suited to address many protein targets that cannot be modulated effectively by traditional small molecule pharmaceutical compounds. Macrocycles have been challenging to synthesize in large numbers and this has constrained their wider use in the industry. By extending beyond the limits of traditional small molecule drug discovery, Ensemble’s platform provides unmatched capabilities to successfully and reliably generate millions of macrocyclic Ensemblins as drug candidates, larger than any collection previously synthesized in the pharmaceutical industry
